A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elucidation of the genetic factors underlying chronic liver disease may reveal new therapeutic targets. METHODS: We used exome sequence data and electronic health records from 46,544 participants in the DiscovEHR human genetics study to identify genetic variants associated with serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Variants that were replicated in three additional cohorts (12,527 persons) were evaluated for association with clinical diagnoses of chronic liver disease in DiscovEHR study participants and two independent cohorts (total of 37,173 persons) and with histopathological severity of liver disease in 2391 human liver samples. RESULTS: ). Among DiscovEHR study participants, this variant was associated with a reduced risk of alcoholic liver disease (by 42% [95% confidence interval {CI}, 20 to 58] among heterozygotes and by 53% [95% CI, 3 to 77] among homozygotes), nonalcoholic liver disease (by 17% [95% CI, 8 to 25] among heterozygotes and by 30% [95% CI, 13 to 43] among homozygotes), alcoholic cirrhosis (by 42% [95% CI, 14 to 61] among heterozygotes and by 73% [95% CI, 15 to 91] among homozygotes), and nonalcoholic cirrhosis (by 26% [95% CI, 7 to 40] among heterozygotes and by 49% [95% CI, 15 to 69] among homozygotes). Associations were confirmed in two independent cohorts. The rs72613567:TA variant was associated with a reduced risk of nonalcoholic steatohepatitis, but not steatosis, in human liver samples. The rs72613567:TA variant mitigated liver injury associated with the risk-increasing PNPLA3 p.I148M allele and resulted in an unstable and truncated protein with reduced enzymatic activity. CONCLUSIONS: A loss-of-function variant in HSD17B13 was associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis. (Funded by Regeneron Pharmaceuticals and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides PNPLA3 p.I148M and TM6SF2 p.E167K, additional variants, including common risk variants in MBOAT7 , GCKR , GPAM , protective variants in HSD17B13 , APOE and MTARC1, and rare variants ( e.g. in APOB , MTTP, CIDEB and ATG7 ), have been robustly associated with the risk of progressive MASLD. 199 -205”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [200]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in the periportal hepatocyte-enriched genes HSD17B13152 and PNPLA3153 are associated with NASH”
From Distinct hepatocyte identities in liver homeostasis and regeneration (2023) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some of the most important human metabolic disease genes have been identified using germline genetic methods such as GWAS and whole exome sequencing42-44.”
From Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease (2023) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“To demonstrate this, we examined the trans associations with a splice variant in HSD17B13 (rs72613567), known to protect against chronic liver disease42.”
From Rare variant associations with plasma protein levels in the UK Biobank (2023) · cites this paper as [42]
In the citing paper
“These findings inform the prioritization of therapeutic targets, providing clues to potential on-target side effects and opportunities for drug repurposing87–89.”
From A brief history of human disease genetics (2020) · cites this paper as [88]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Self-citationGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Self-citationWilliams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Self-citationKozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234
Self-citationYounossi, Z. M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H., & Srishord, M. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.020 · Cited by 1,073
Lazo, M., Hernaez, R., Eberhardt, M. S., Bonekamp, S., Kamel, I., Guallar, E., Koteish, A., Brancati, F. L., & Clark, J. M. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws448 · Cited by 797
Mancina, R. M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., Borén, J., Montalcini, T., Pujia, A., Wiklund, O., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.032 · Cited by 676
Self-citationLiu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623
Self-citationBuch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565
Cited by
Items 301–400 of 831
Scheiner, B., Stättermayer, A. F., Schwabl, P., Bucsics, T., Paternostro, R., Bauer, D. J. M., Simbrunner, B., Schmidt, R. L. J., Marculescu, R., Ferlitsch, A., et al. (2019) · Liver International · doi:10.1111/liv.14304 · Cited by 30
“well as MELD scores (12 (10-15) vs 11 (9-13) points; P = .”
Recent advances in alcoholic hepatitis
Rachakonda, V. P., Bataller, R. A., & Duarte‐Rojo, A. (2020) · F1000Research · doi:10.12688/f1000research.20394.1 · Cited by 34
Genetic Susceptibility to Chronic Liver Disease in Individuals from Pakistan
Raja, A. M., Ciociola, E., Ahmad, I., Dar, F. S., Naqvi, S., Moaeen-ud-Din, M., Raja, G. K., Romeo, S., & Mancina, R. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103558 · Cited by 28
“Recently, the Hydroxysteroid 17-Beta Dehydrogenase 13 (HSD17B13) rs7261356 [14,15] and the Protein Phosphatase 1 Regulatory Subunit 3B (PPP1R3B) rs4841132 [16,17] have been shown to confer protection against liver disease, at least in at-risk individuals, instead.”
BackgroundInfluentialCaputo, M., Kurhe, Y., Kumari, S., Cansby, E., Amrutkar, M., Scandalis, E., Booten, S. L., Ståhlman, M., Borén, J., Marschall, H., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202002671rr · Cited by 29
Traspas, R. M., Teoh, T. S., Wong, P., Maier, M., Chia, C. Y., Lay, K., Ali, N. A., Larson, A. A., Mutairi, F. A., Al-Sannaa, N. A., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01120-0 · Cited by 30
The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition
Momtazi‐Borojeni, A. A., Banach, M., Ruscica, M., & Sahebkar, A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2132229 · Cited by 28
Genetic Polymorphisms and Diversity in Nonalcoholic Fatty Liver Disease (NAFLD): A Mini Review
Sulaiman, S. A., Dorairaj, V., & Adrus, M. N. H. (2022) · Biomedicines · doi:10.3390/biomedicines11010106 · Cited by 33
“European, Finnish Associated with lower NASH and fibrosis risk [111,112] Argentinian, Japanese Associated with lower NASH risk [113,114] Korean Associated with lower NAFLD risk [115] Abbreviation: GCKR: glucokinase regulatory protein; HSD17B13: hydroxysteroid 17 β -dehydrogenase; MBOAT7:…”
BackgroundElucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease
Li, Y., Qi, P., Song, S., Wang, Y., Wang, H., Cao, P., Liu, Y., & Wang, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116585 · Cited by 29
Self-citationDíaz, L. A., Ajmera, V. H., Arab, J. P., Huang, D. Q., Hsu, C. L., Lee, B. P., Louvet, A., Thiele, M. S., Tavaglione, F., Tincopa, M. A., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.02.017 · Cited by 34
The pathogenesis of hepatic steatosis in MASLD: a lipid droplet perspective
Krahmer, N., Walther, T. C., & Farese, R. V. (2025) · Journal of Clinical Investigation · doi:10.1172/jci198334 · Cited by 35
“Multiple loss-of-function variants of it lead to inactive forms of the enzyme, associated with a reduced risk of progression to MASH and hepatocellular carcinoma (19).”
Rinella, M. E., & Sookoian, S. C. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01187-8 · Cited by 34
“Genome-wide association studies identified gene variants such as PNPLA3 , TM6SF2 and HSD17B13 , which together account for up to 30% of MASLD heritability 132–134 .”
Identification and Replication of Six Loci Associated With Gallstone Disease
Gellert‐Kristensen, H., Dalila, N., Nielsen, S. F., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Stender, S. (2019) · Hepatology · doi:10.1002/hep.30313 · Cited by 33
“A recent exome-wide association study of 46,544 US individuals found the variant to be associated with increased ALT, as expected.(38) Six lithogenic variants were paradoxically associated with slightly reduced plasma levels of alkaline phosphatase in our study.”
BackgroundSelf-citationHCV-Associated Liver Fibrosis and HSD17B13
About, F., Abel, L., & Cobat, A. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1804638 · Cited by 27
González-Prendes, R., Mármol‐Sánchez, E., Quintanilla, R., Castelló, A., Zidi, A., Ramayo‐Caldas, Y., Cardoso, T. F., Manunza, A., Cánovas, Á., & Amills, M. (2019) · BMC Genomics · doi:10.1186/s12864-019-5889-5 · Cited by 41
Sessa, A. D., Umano, G. R., Cirillo, G., Marzuillo, P., Arienzo, M. R., Pedullà, M., & del Giudice, E. M. (2019) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002573 · Cited by 27
“Recently, Abul-Husn et al (7) reported that the loss-offunction variant (rs72613567:TA) of the hepatic lipid droplet protein hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) gene was associated with reduced risk of NAFLD and alcoholic fatty liver disease (AFLD) in adults.”
BackgroundResultMoolla, A., de Boer, J., Pavlov, D., Amin, A., TAYLOR, A. E. R., Gilligan, L. C., Hughes, B. A., Ryan, J. D., Barnes, E. J., Hassan-Smith, Z. K., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15710 · Cited by 27
Chen, H., Zhang, Y., Guo, T., Yang, F., Mao, Y., Li, L., Liu, C., Gao, H., Jin, Y., Che, Y., et al. (2020) · Liver International · doi:10.1111/liv.14616 · Cited by 27
Serper, M., Vujković, M., Kaplan, D. E., Carr, R. M., Lee, K. M., Shao, Q., Miller, D. R., Reaven, P. D., Phillips, L. S., O’Donnell, C. J., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237430 · Cited by 28
Self-citationPediatric non-alcoholic fatty liver disease and kidney function: Effect of HSD17B13 variant
Sessa, A. D., Umano, G. R., Cirillo, G., Passaro, A. P., Verde, V. L., Cozzolino, D., Guarino, S., Marzuillo, P., & del Giudice, E. M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i36.5474 · Cited by 28
Patients with Protein-Truncating PKD1 Mutations and Mild ADPKD
Lanktree, M. B., Guiard, E., Akbari, P., Pourafkari, M., Iliuta, I.-A., Ahmed, S. I., Haghighi, A., He, N., Song, X., Paterson, A. D., et al. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11100720 · Cited by 29
“, rs72613567:TA) variant of the hepatic lipid droplet protein hydroxysteroid 17-beta dehydrogenase (HSD17B13), present in approximately 25% of European population, protects against nonalcoholic steatohepatitis (42).”
BackgroundHeterozygosity of the Alpha 1‐Antitrypsin Pi*Z Allele and Risk of Liver Disease
Hakim, A., Moll, M. R., Qiao, D., Liu, J., Lasky-Su, J. A., Silverman, E. K., Vilarinho, S., Jiang, Z. G., Hobbs, B. D., & Cho, M. H. (2021) · Hepatology Communications · doi:10.1002/hep4.1718 · Cited by 27
The lipidome in nonalcoholic fatty liver disease: actionable targets
Pirola, C. J., & Sookoian, S. C. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100073 · Cited by 30
Computational analysis of neurodevelopmental phenotypes: Harmonization empowers clinical discovery
Lewis‐Smith, D., Parthasarathy, S., Xian, J., Kaufman, M. C., Ganesan, S., Galer, P. D., Thomas, R. H., & Helbig, I. (2022) · Human Mutation · doi:10.1002/humu.24389 · Cited by 21
“These combined resources have been used to identify the protective effect of ANGPTL4 for coronary artery disease and type 2 diabetes (Dewey et al., 2016; Gusarova et al., 2018), and a reduced risk of chronic liver disease in patients with variants in HSD17B13 (Abul ‐ Husn et al., 2018).”
MethodMetabolic disease as a risk of hepatocellular carcinoma
Nishida, N. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0302 · Cited by 29
“As metabolic perturbations affect gene expression and molecular alteration, and vice versa, making efforts to understand the influence of obesity and lifestyle events is becoming critical for achieving effective management of the emergence of metabolic disease-related HCC. Conflicts of Interest The author has no confl…”
BackgroundInfluentialFelzen, A., van Wessel, D. B. E., Gonzales, E. M., Thompson, R. J., Jankowska, I., Shneider, B. L., Sokal, E. M., Grammatikopoulos, T., Kadaristiana, A., Jacquemin, E., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100626 · Cited by 31
Gao, E., Hercun, J., Heller, T., & Vilarinho, S. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2020.04.04 · Cited by 30
Genetics and epigenetics purpose in nonalcoholic fatty liver disease
Botello-Manilla, A. E., Chávez-Tapia, N. C., Uribe, M., & Nuño‐Lámbarri, N. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1780915 · Cited by 33
Review article: current and emerging therapies for acute alcohol‐associated hepatitis
Rattan, P., & Shah, V. H. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16969 · Cited by 30
From Non-Alcoholic Fatty Liver to Hepatocellular Carcinoma: A Story of (Mal)Adapted Mitochondria
Amorim, R., Magalhães, C. C., Borges, F., Oliveira, P. J., & Teixeira, J. (2023) · Biology · doi:10.3390/biology12040595 · Cited by 35
Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Zhou, D., & Fan, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003355 · Cited by 30
Ajmera, V., Liu, A., Bettencourt, R., Dhar, D., Richards, L., & Loomba, R. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16392 · Cited by 25
Gao, C., Marcketta, A., Backman, J., O’Dushlaine, C. T., Staples, J. C., Ferreira, M. A. R., Lotta, L. A., Overton, J. D., Reid, J. G., Mirshahi, T., et al. (2021) · Genetic Epidemiology · doi:10.1002/gepi.22392 · Cited by 29
Self-citationGenomic medicine for liver disease
Zheng, M., Allington, G., & Vilarinho, S. (2022) · Hepatology · doi:10.1002/hep.32364 · Cited by 28
“In fact, leveraging electronic health systems data has identified risk and protective variants for liver disease.[47,69] Hence, we envision a new era of molecular diagnostics and therapeutics in hepatology.”
BackgroundDaniali, M., Galer, P. D., Lewis‐Smith, D., Parthasarathy, S., Kim, E., Salvucci, D. D., Miller, J. M., Haag, S., & Helbig, I. (2022) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2023.102523 · Cited by 27
Nanodrug Delivery Systems for Metabolic Chronic Liver Diseases: Advances and Perspectives
Athanasopoulou, F., Manolakakis, M., Vernia, S., & Kamaly, N. (2023) · Nanomedicine · doi:10.2217/nnm-2022-0261 · Cited by 30
Drug development advances in human genetics‐based targets
Zhang, X., Yu, W., Li, Y., Wang, A., Cao, H., & Fu, Y. (2024) · MedComm · doi:10.1002/mco2.481 · Cited by 31
“In 2018, Abul-Husn et al. 212 performed WES on 46,544 Americans and found that the HSD17B13 LOF mutation (rs72613567:TA) was associated with chronic liver disease, 213 risk of progression from steatosis to steatohepatitis, and reduced plasma alanine aminotransferase (ALT) and glutamate amino-transferase (AST) levels,…”
BackgroundBellan, M., Colletta, C., Barbaglia, M. N., Salmi, L., Clerici, R., Mallela, V. R., Castello, L. M., Saglietti, G., Schianca, G. P. C., Minisini, R., et al. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0201 · Cited by 27
Mechanisms coupling lipid droplets to MASLD pathophysiology
Reid, M. V., Fredrickson, G., & Mashek, D. G. (2024) · Hepatology · doi:10.1097/hep.0000000000001141 · Cited by 29
Raschi, E., Mazzotti, A., Poluzzi, E., Ponti, F. D., & Marchesini, G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1531126 · Cited by 29
Combined effects of lifestyle risk factors on fatty liver index
Nivukoski, U., Niemelä, M., Bloigu, A. H., Bloigu, R., Aalto, M., Laatikainen, T. K., & Niemelä, O. J. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01270-7 · Cited by 28
Sookoian, S. C., & Pirola, C. J. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-20-270 · Cited by 25
Tavaglione, F., Vincentis, A. D., Jamialahmadi, O., Pujia, R., Spagnuolo, R., Picardi, A., Morano, S., Valenti, L. V. C., Romeo, S., & Gentilucci, U. V. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100262 · Cited by 25
Motomura, T., Amirneni, S., Díaz‐Aragon, R., Faccioli, L. A. P., Malizio, M. R., Coard, M. C., Kocas‐Kilicarslan, Z. N., Frau, C., Haep, N., Ostrowska, A., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070619 · Cited by 25
Thamm, S., Willwacher, M. K., Aspnes, G. E., Bretschneider, T., Brown, N. F., Buschbom-Helmke, S., Fox, T., Gargano, E. M., Grabowski, D., Hoenke, C., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01884 · Cited by 24
The association between telomere length and non-alcoholic fatty liver disease: a prospective study
Tang, L., Li, D., Ma, Y., Cui, F., Wang, J., & Tian, Y. (2023) · BMC Medicine · doi:10.1186/s12916-023-03136-7 · Cited by 31
Leslie, J., Krishnamurthy, K. A., Gopalsamy, I. K., Inácio, P., Huch, M., Gallage, S., Oakley, F., & Vacca, M. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01162-9 · Cited by 30
Retinoic Acid: A New Old Friend of IL-17A in the Immune Pathogeny of Liver Fibrosis
Kartasheva-Ebertz, D., Pol, S., & Lagaye, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691073 · Cited by 25
“Biological function of HSD17B13 is not clear: when overexpressed, the size and number of lipid droplets in hepatocytes is increased (68), but this remains debated (69).”
BackgroundMechanisms of Lipid Droplet Accumulation in Steatotic Liver Diseases
Dempsey, J. L., Ioannou, G. N., & Carr, R. M. (2023) · Seminars in Liver Disease · doi:10.1055/a-2186-3557 · Cited by 26
Suresh, D., Li, A., Miller, M. J., Wijarnpreecha, K., & Chen, V. L. (2023) · Liver International · doi:10.1111/liv.15787 · Cited by 27
“20,21 Analysis of rare variants using whole-exome sequencing has identified rare mutations in genes associated with iron homeostasis that are enriched in patients with MASLD and hy-perferritinaemia.”
BackgroundSelf-citationReview of current and new drugs for the treatment of metabolic-associated fatty liver disease
Gish, R. G., Fan, J., Dossaji, Z., Fichez, J., Laeeq, T., Chun, M. J., & Boursier, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10698-y · Cited by 26
“RNA interference therapy is already under evaluation in MASH with the example of ARO-HSD, a small-interfering RNA designed to silence HSD17β13 whose loss-of-function mutations have been associated with protection against MASH related-cirrhosis in human genetic studies [120].”
Biomarker and Genomic Risk Factors for Liver Function Test Abnormality in Hazardous Drinkers
Whitfield, J. B., Zhu, G., Madden, P. A. F., Montgomery, G. W., Heath, A. C., & Martin, N. G. (2018) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13949 · Cited by 24
Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective
Yu, B. C.-Y., Kwok, D., & Wong, V. W. (2019) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2019.01.007 · Cited by 27
“9 Recently, exome sequence data from several large cohorts have identified hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13 rs72613567) as a protective factor against NAFLD, histological NASH and alcohol-related liver disease.(34) Data from Asia are eagerly awaited.”
BackgroundMederacke, Y., Kirstein, M. M., Großhennig, A., Marhenke, S., Metzler, F., Manns, M. P., Vogel, A., & Mederacke, I. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15722 · Cited by 23
Rutledge, S. M., Soper, E. R., Ma, N., Pejaver, V., Friedman, S. L., Branch, A. D., Kenny, E. E., Belbin, G. M., & Abul-Husn, N. S. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.12.025 · Cited by 22
Self-citationAdvancements in MAFLD Modeling with Human Cell and Organoid Models
Wang, S.-X., Yan, J.-S., & Chan, Y.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911850 · Cited by 22
“Conversely, a protective single-nucleotide polymorphism (SNP) variant on the HSD17B13 gene locus was identified in an independent cohort [17].”
BackgroundNag, A., Dhindsa, R. S., Middleton, L., Jiang, X., Vitsios, D., Wigmore, E., Allman, E. L., Reznichenko, A., Carss, K., Smith, K. R., et al. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.02.002 · Cited by 22
“First, by virtue of focusing on coding variants, the observed associationsmoreoftenprovide adirect causal link betweenvariants in a gene and a metabolic trait.(35,45,47,48) Moreover, collapsing analyses draw their power from aggregating the signals of multiple rare variants (allelic series), which tend to be less impa…”
BackgroundReview article: Hepatic steatosis and its associations with acute and chronic liver diseases
Koenig, A. B., Tan, A., Abdelaal, H., Monge, F., Younossi, Z. M., & Goodman, Z. D. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18059 · Cited by 29
“268 The same authors 268 also found that rs72613567 was associated with decreased PNPLA3 expression and was hepatoprotective in people with PNPLA3 p.I148M.”
BackgroundTao, Z., Li, Y., Cheng, B., Zhou, T., & Gao, Y. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00171 · Cited by 25
Rábeková, Z., Fraňková, S., Jirsa, M., Neřoldová, M., Lunová, M., Fabián, O., Květoň, M., Varyš, D., Chmelova, K., Adámková, V., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910560 · Cited by 22
“The absolute risk of liver cirrhosis in MZ heterozygotes has not been established so far; however, it increased the risk of liver cirrhosis in studies on patients with chronic liver disease of various aetiologies [18].”
BackgroundAssociazione Italiana per lo Studio del Fegato (AISF), S. I. D. D. (. A. S. I. D. (. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-021-01287-1 · Cited by 22
Goodarzi, G., Tehrani, S. S., Panahi, G., Bahramzadeh, A., & Meshkani, R. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109369 · Cited by 23
17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease
Wang, M., & Peng, Z. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108428 · Cited by 24
Mahmoudi, S. K., Tarzemani, S., Aghajanzadeh, T., Kasravi, M., Hatami, B., Zali, M. R., & Baghaei, K. (2024) · European journal of medical research · doi:10.1186/s40001-024-01708-8 · Cited by 28
“Accordingly, they proposed HSD17B13 inhibition as a potential strategy to modify the risk of NAFLD progression in PNPLA3 148M allele carriers [35].”
BackgroundKirpich, I., Warner, D. R., Feng, W., Joshi‐Barve, S., McClain, C. J., Seth, D., Zhong, W. H., Zhou, Z., Osna, N. A., & Kharbanda, K. K. (2019) · Alcohol · doi:10.1016/j.alcohol.2019.05.004 · Cited by 22
Physiopathologie des stéatoses hépatiques métaboliques
Anty, R., & Gual, P. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.09.051 · Cited by 33
Characterizing the Mechanism Behind the Progression of NAFLD to Hepatocellular Carcinoma
Nahon, P., Allaire, M., Nault, J., & Paradis, V. (2020) · Hepatic Oncology · doi:10.2217/hep-2020-0017 · Cited by 27
“Finally, the rs72613567variant of HSD17B13 was recently identified as a protective factor of NAFLD progression leading to production of a truncated protein with a reduced enzymatic activity [21].”
BackgroundInfluentialMa, J., Ma, Y., Wan, X., Li, J., Zhang, Y., Liu, J., & Gao, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1639064 · Cited by 26
“Evidence suggests that the rs72613567:TA variant may attenuate the deleterious hepatic effects of the PNPLA3 I148M mutation, as re fl ected by lower serum transaminase levels and reduced hepatic in fl ammation (97).”
Steatotic liver disease and cancer: from pathogenesis to therapeutic targets
Yang, Z., Liu, Z., Liu, W., & Dong, X. C. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100218 · Cited by 33
“13 Further, this PNPLA3 variant has been shown to be resistant to ubiquitin-mediated protein degradation, 14 15 for example, by an E3 ubiquitin ligase bifunctional apoptosis regulator, 16 17 and competitive binding to abhydrolase domain containing 5 (ABHD5, or known as CGI-58) with adipose…”
InfluentialMechanisms and therapeutic insights into MASH-associated fibrosis
Zhu, Y., & Cai, B. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.09.004 · Cited by 32
Genomics of drug target prioritization for complex diseases
Chen, R. K., Duffy, Á., & Do, R. (2025) · Nature Reviews Genetics · doi:10.1038/s41576-025-00904-4 · Cited by 30
Lipid droplet dynamics in alcoholic fatty liver disease
Schulze, R. J., & Ding, W. (2019) · Liver Research · doi:10.1016/j.livres.2019.09.002 · Cited by 21
Caputo, M., Cansby, E., Kumari, S., Kurhe, Y., Nair, S., Ståhlman, M., Kulkarni, N. M., Borén, J., Marschall, H., Blüher, M., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1702 · Cited by 21
Genetics of Kidney Disease: The Unexpected Role of Rare Disorders
Elliott, M. D., Rasouly, H. M., & Gharavi, A. G. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-101813 · Cited by 24
Non-alcoholic Fatty Liver Disease in Children
Muzurović, E. M., Pοlyzos, S. A., Mikhailidis, D. P., Borozan, S., Novosel, D., Cmiljanić, O., Kadić, N., & Mantzoros, C. S. (2022) · Current Vascular Pharmacology · doi:10.2174/1570161121666221118155136 · Cited by 25
Pirola, C. J., Flichman, D., Dopazo, H., Gianotti, T. F., Martino, J. S., Rohr, C., Garaycoechea, M. E., Gazzi, C., Castaño, G. O., & Sookoian, S. C. (2018) · Hepatology Communications · doi:10.1002/hep4.1235 · Cited by 21
HSD17B13 truncated variant is associated with a mild hepatic phenotype in Wilson’s Disease
Ferenci, P., Pfeiffenberger, J., Stättermayer, A. F., Stauber, R. E., Willheim, C., Weiss, K. H., Munda-Steindl, P., Trauner, M., Schilsky, M. L., & Zoller, H. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.02.007 · Cited by 22
“5%, comparable to published data in Caucasians.(1)”
BackgroundInfluentialGenetic and Metabolic Determinants of Plasma Levels of ANGPTL8
Oldoni, F., Bass, K., Kozlitina, J., Hudson, H., Shihanian, L. M., Gusarova, V., Cohen, J. C., & Hobbs, H. H. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab120 · Cited by 21
Self-citationKanda, T., Sasaki, R., Abé, H., Kimura, N., Yoshida, T., Hayashi, K., Sakamaki, A., Yokoo, T., Kamimura, H., Tsuchiya, A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115164 · Cited by 25
“A loss-of-function variant in HSD17B13 was related to a reduced risk of progression from steatosis to steatohepatitis [65].”
Genetic and non-genetic drivers of histological progression and regression in MASLD
Gómez, E. V., Yates, K. P., Kleiner, D. E., Behling, C. A., Cummings, O. W., Wilson, L., Liang, T., Jarasvaraparn, C., Loomba, R., Schwimmer, J. B., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.09.013 · Cited by 29
Sunami, Y., Rebelo, A., & Kleeff, J. H. (2021) · Cancers · doi:10.3390/cancers13174391 · Cited by 22
What’s new in non-alcoholic fatty liver disease?
Spiers, J., Brindley, J. H., Li, W., & Alazawi, W. (2022) · Frontline Gastroenterology · doi:10.1136/flgastro-2022-102122 · Cited by 26
Song, J., & Jiang, Z. G. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000124 · Cited by 21
“…TA), a splice variant that leads to an unstable, truncated protein, reduces the risk of NAFLD, alcohol-associated liver disease (ALD) and HCC. [14,15] Previous studies suggested that vitamin A deficiency is more prevalent in patients awaiting liver transplant, and circulating retinol level is…”
Advances in genetic variation in metabolism-related fatty liver disease
Shi, F., Zhao, M., Zheng, S., Zheng, L., & Wang, H. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1213916 · Cited by 22
“A genetic variant of HSD17B13 (rs72613567, T > TA) was first described in 2018 and was associated with a reduced risk of MAFLD (Abul-Husn et al., 2018), other variants of HSD17B13 (rs6834314, A > G and rs9992651, G > A) were later associated with lower inflammatory scores in patients with MAFLD, which may be related t…”
Seko, Y., Yamaguchi, K., Shima, T., Iwaki, M., Takahashi, H., Kawanaka, M., Tanaka, S., Mitsumoto, Y., Yoneda, M., Nakajima, A., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.02.031 · Cited by 23
Future directions for high‐throughput splicing assays in precision medicine
Rhine, C. L., Neil, C. R., Glidden, D. T., Cygan, K. J., Fredericks, A. M., Wang, J., Walton, N., & Fairbrother, W. G. (2019) · Human Mutation · doi:10.1002/humu.23866 · Cited by 23
“DiscovEHR has already been proven to be a tremendous resource for genomic discovery (Abul ‐ Husn et al., 2018; Gusarova et al., 2018; Verma et al., 2019).”
Thousands of missing variants in the UK Biobank are recoverable by genome realignment
Jia, T., Munson, B. P., Allen, H. L., Ideker, T., & Majithia, A. R. (2020) · Annals of Human Genetics · doi:10.1111/ahg.12383 · Cited by 23
“Such comprehensive cataloging of protein-coding variation across the entire allele frequency spectrum, attached to extensive clinical phenotyping, has the potential to accelerate biomedical discovery, as evidenced by recent successes with other exome biobanks 2 .”
BackgroundOmics‐derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases
Fujiwara, N., Qian, T., Koneru, B., & Hoshida, Y. (2020) · Hepatology Research · doi:10.1111/hepr.13506 · Cited by 20
Deng, Y., Li, Z., Huang, Y., Zhong, Y., Qiu, A., Chen, X., Huang, X., Yang, X., Feng, Y., Bai, R., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.055 · Cited by 19
“Membranes were blocked in 5 % skim milk (Cell Signaling Technology, #9999 s) and probed with primary antibodies (anti-HSD17B13 [26,27], Thermo Fisher, #PA5-109834, 1:1000 dilution; anti-b -ACTIN, Proteintech, #66009–1-Ig, 1:5000 dilution) overnight at 4 ° C.”
Hakim, A., Moll, M. R., Brancale, J., Liu, J., Lasky-Su, J. A., Silverman, E. K., Vilarinho, S., Jiang, Z. G., Pita-Juárez, Y. H., Vlachos, I. S., et al. (2021) · Hepatology · doi:10.1002/hep.32038 · Cited by 19
4-Methylumbelliferone Targets Revealed by Public Data Analysis and Liver Transcriptome Sequencing
Tsitrina, A. A., Halimani, N., Andreichenko, I. N., Sabirov, M. S., Nesterchuk, M. V., Dashenkova, N. O., Romanov, R. A., Bulgakova, E. V., Mikaelyan, A. S., & Kotelevtsev, Y. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032129 · Cited by 21
Hegarty, R., Kyrana, E., Fitzpatrick, E., & Dhawan, A. (2023) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231160388 · Cited by 27
Reinshagen, M., Kabisch, S., Pfeiffer, A. F. H., & Spranger, J. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00019 · Cited by 34
Genetics of liver disease in adults
Konkwo, C., Chowdhury, S., & Vilarinho, S. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000408 · Cited by 23
“[27,28] Both HSD17B13 and CIDEB encode proteins which associate with lipid droplets.”
BackgroundLyu, S., Cai, Z., Yang, Q., Liu, J., Yu, Y., Pan, F., & Zhang, T. (2024) · Food Chemistry · doi:10.1016/j.foodchem.2024.139337 · Cited by 22
Zhang, X., Chang, K., Yu, J. Q., & Loomba, R. S. (2025) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-111523-023430 · Cited by 21
SERPINA1 and HSD17B13 Gene Variants in Patients with Liver Fibrosis and Cirrhosis
Basytė-Bacevičė, V., Skiecevičienė, J., Valantienė, I., Šumskienė, J., Petrenkienė, V., Kondrackienė, J., Petrauskas, D., Lammert, F., & Kupčinskas, J. (2019) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-168 · Cited by 19
“[18]) and the risk of liver fibrosis or cirrhosis of different aetiology in an Eastern European patient cohort.”
BackgroundMethodResultInfluentialHamesch, K., & Strnad, P. (2020) · Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation · doi:10.15326/jcopdf.7.3.2019.0161 · Cited by 25
Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk
Kubota, N., Fujiwara, N., & Hoshida, Y. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123843 · Cited by 21
Sood, V., Alam, S., Nagral, A. S., Srivastava, A., Deshmukh, A., Bavdekar, A., Acharyya, B. C., Geetha, S., Gupte, G. L., Bhatia, I., et al. (2024) · Indian Pediatrics · doi:10.1007/s13312-024-3290-1 · Cited by 19
“…for variations in other genes, such as membrane-bound O-acyltransferase domain-containing 7 (MBOAT7), glucokinase regulator ( GCKR), and hydroxyl steroid 17-beta dehydrogenase 13 (HSD17B13, associated with increased steatosis but decreased inflammation) amongst others [51-53] ( Web Table IV ).”
BackgroundRegulation of lipid droplet dynamics and lipid homeostasis by hydroxysteroid dehydrogenase proteins
Liang, B., Fu, L., & Liu, P. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.10.010 · Cited by 23
Metadata
- Authors
- Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., Stepanchick, A. N., Still, M. D., McCarthy, S., O’Dushlaine, C., Packer, J. S., Balasubramanian, S., Gosalia, N., Esopi, D., Kim, S. Y., Mukherjee, S., Lopez, A. E., Fuller, E. D., Penn, J., Chu, X., Luo, J. Z., Mirshahi, U. L., Carey, D. J., Still, C. D., Feldman, M. D., Small, A., Damrauer, S. M., Rader, D. J., Zambrowicz, B., Olson, W., Murphy, A. J., Borecki, I. B., Shuldiner, A. R., Reid, J. G., Overton, J. D., Yancopoulos, G. D., Hobbs, H. H., Cohen, J. C., Gottesman, O., Teslovich, T. M., Baras, A., Mirshahi, T., Gromada, J., & Dewey, F. E.
- Affiliations
- From the Regeneron Genetics Center (N.S.A.-H., A.H.L., C.S., S. McCarthy, C.O., J.S.P., S.B., N.G., S. Mukherjee, A.E.L., E.D.F., J.P., I.B.B., A.R.S., J.G.R., J.D.O., O.G., T.M.T., A.B., F.E.D.) and Regeneron Pharmaceuticals (X. Cheng, Y.X., P.S., Y.L., D.E., S.Y.K., B.Z., W.O., A.J.M., G.D.Y., J.G.), Tarrytown, NY; the University of Texas Southwestern Medical Center at Dallas, Dallas (J.K., S.S., H.H.H., J.C.C.); and Geisinger Health System, Danville (G.C.W., A.N.S., M.D.S., X. Chu, J.Z.L., U.L.M....
- Regeneron (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Geisinger Health System (US)
- University of Pennsylvania (US)
- ORCID
- Cheng, Xiping
- Li, Alexander H.
- Xin, Yurong
- Schurmann, Claudia
- Liu, Yashu
- Kozlitina, Julia
- Stender, Stefan
- Wood, G. Craig
- Still, Matthew D.
- O’Dushlaine, Colm
- Packer, Jonathan S.
- Balasubramanian, Suganthi
- Gosalia, Nehal
- Esopi, David
- Kim, Sun Y.
- Mukherjee, Semanti
- Lopez, Alexander E.
- Chu, Xin
- Luo, Jonathan Z.
- Mirshahi, Uyenlinh L.
- Carey, David J.
- Still, Christopher D.
- Feldman, Michael D.
- Small, Aeron
- Damrauer, Scott M.
- Rader, Daniel J.
- Zambrowicz, Brian
- Olson, William
- Murphy, Andrew J.
- Borecki, Ingrid B.
- Shuldiner, Alan R.
- Reid, Jeffrey G.
- Overton, John D.
- Hobbs, Helen H.
- Cohen, Jonathan C.
- Baras, Aris
- Mirshahi, Tooraj
- Gromada, Jesper
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03-22
- Volume
- 378
- Issue
- 12
- Pages
- 1096-1106
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6668033
- OpenAlex
- W2793543636
- Cited by
- 827
- References
- 32
- Citations by year
- 2026: 101 · 2025: 104 · 2024: 82 · 2023: 104 · 2022: 100 · 2021: 109 · 2020: 127 · 2019: 67 · 2018: 32
- FWCI
- 48.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Regeneron Pharmaceuticals
- Perelman School of Medicine, University of Pennsylvania
- Smilow Foundation
- National Institutes of Health (P30DK072488, UL1TR001105)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- HSD17B13, chronic liver disease, loss-of-function mutations, alcoholic liver disease, non-alcoholic liver disease, alcoholic cirrhosis, non-alcoholic cirrhosis, nonalcoholic steatohepatitis, steatosis, alanine aminotransferase, aspartate aminotransferase, PNPLA3, liver histopathology
- MeSH terms
- Exome Sequencing, Loss of Function Mutation, Alanine Transaminase, Aspartate Aminotransferases, Chronic Disease, Fatty Liver, Female, Genotype, Humans, Liver, Liver Diseases, Male, Genetic Variation, 17-Hydroxysteroid Dehydrogenases, Biomarkers, Linear Models, Sequence Analysis, RNA, Disease Progression, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.